Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo

A Corrigendum to this article was published on 01 November 1995

Abstract

CD23 is a low-affinity receptor for immunoglobulin E (IgE) expressed by a variety of haematopoietic cells. Proteolytic cleavage of the transmembrane receptor generates soluble forms, which can be detected in biological fluids. CD23 regulates many functional aspects of immune cells, both in its cell-associated and soluble forms. In view of the increased levels of CD23 in rheumatoid arthritis, we have studied the effect of neutralizing CD23 in type II collagen-induced arthritis in mice, a model for human rheumatoid arthritis. Successful disease modulation is achieved by treatment of arthritic DBA/1 mice with either polyclonal or monoclonal antibodies to mouse CD23. Treated mice show a dose-related amelioration of arthritis with significantly reduced clinical scores and number of affected paws. This improvement in clinical severity is confirmed by histological examination of the arthritic paws. A marked decrease in cellular infiltration of the synovial sublining layer and limited destruction of cartilage and bone is evident in animals treated with therapeutic doses of anti-CD23 antibody. These findings demonstrate the involvement of CD23 in a mouse model of human rheumatoid arthritis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Conrad, D.H. Fc epsilon RII/CD23: The low Affinity receptor for IgE. Annu. Rev. Immun. 8, 623–645 (1990).

    Article  CAS  Google Scholar 

  2. Delespesse, G. et al. Expression, structure, and function of the CD23 antigen. Adv. Immun. 49, 149–191 (1991).

    Article  CAS  Google Scholar 

  3. Bonnefoy, J.Y. et al. Receptors for IgE. Curr. Opin. Immun. 5, 944–949 (1993).

    Article  CAS  Google Scholar 

  4. Lecoanet-Henchoz, S. et al. CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD lib/CD 18 and CDllc/CD18. Immunity (in the press).

  5. Herbelin, A., Elhadad, S., Ouaaz, F., de Groote, D. & Descamps-Latscha, B. Soluble CD23 potentiates interleukin-1-induced secretion of interleukin-6 and interleukin-1 receptor antagonist by human monocytes. Eur. J. Immun. 24, 1869–1873 (1994).

    Article  CAS  Google Scholar 

  6. Armant, M., Ishihara, H., Rubio, M., Delespesse, G. & Sarfati, M. Regulation of cytokine production by soluble CD23: Costimulation of interferon gamma secretion and triggering of tumor necrosis factor a release. J. exp. Med. 180, 1005–1011 (1994).

    Article  CAS  Google Scholar 

  7. Bansal, A.S., Oilier, W., Marsh, M.N., Pumphrey, R.S. & Wilson, P.B. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology 79, 285–289 (1993).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Hellen, E.A., Rowlands, D.C., Hansel, T.T., Kitas, G.D. & Crocker, J. Immunohistochemical demonstration of CD23 expression on lymphocytes in rheumatoid synovitis. J. clin. Pathol. 44, 293–296 (1991).

    Article  CAS  Google Scholar 

  9. Chomarat, P., Briolay, J., Banchereau, J. & Miossec, P. Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis Rheum. 36, 234–242 (1993).

    Article  CAS  Google Scholar 

  10. Bansal, A. et al. Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus. Clin. exp. Immun. 89, 452–455 (1992).

    Article  CAS  Google Scholar 

  11. Rezonzew, R. & Newkirk, M.M. Impaired release of sCD23 by activated B-cells from RA patients. Clin. Immunol. Immunopathol. 71, 156–163 (1994).

    Article  CAS  Google Scholar 

  12. Bansal, A.S. et al. Increased levels of sCD23 in rheumatoid arthritis are related to disease status. Clin. exp. Rheumatol. 12, 281–285 (1994).

    CAS  PubMed  Google Scholar 

  13. Brennan, F.M., Chantry, D., Jackson, A., Maini, R. & Feldmann, M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244–247 (1989).

    Article  CAS  Google Scholar 

  14. Feldmann, M. et al. Cytokine assays: Role in evaluation of the pathogenesis of autoimmunity. Immunol. Rev. 119, 105–123 (1991).

    Article  CAS  Google Scholar 

  15. Brennan, F.M., Maini, R.N. & Feldmann, M. TNF alpha—A pivotal role in rheumatoid arthritis? Br. J. Rheumatol. 31, 293–298 (1992).

    Article  CAS  Google Scholar 

  16. Chu, C.Q., Field, M., Feldmann, M. & Maini, R.N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1125–1132 (1991).

    Article  CAS  Google Scholar 

  17. Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor-alpha. Arthritis Rheum. 36, 1681–1690 (1993).

    Article  CAS  Google Scholar 

  18. Williams, R.O., Feldmann, M. & Maini, R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. natn. Acad. Sci. U.S.A. 89, 9784–9788 (1992).

    Article  CAS  Google Scholar 

  19. Piguet, P.F. et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77, 510–514 (1992).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Wooley, P.H., Dutcher, J., Widmer, M.B. & Gillis, S. Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J. Immun. 151, 6602–6607 (1993).

    CAS  PubMed  Google Scholar 

  21. Wooley, P.H. et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum. 36, 1305–1314 (1993).

    Article  CAS  Google Scholar 

  22. Van den Berg, W.B., Joosten, L.A.B., Helsen, M. & van de Loo, F.A.J. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. exp. Immun. 95, 237–243 (1994).

    Article  CAS  Google Scholar 

  23. Field, M., Chu, C., Feldmann, M. & Maini, R.N. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol. Int. 11, 45–50 (1991).

    Article  CAS  Google Scholar 

  24. Wendling, D., Racadot, E. & Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20, 259–262 (1993).

    CAS  PubMed  Google Scholar 

  25. Stuart, J.M., Townes, A.S. & Kang, A.H. Collagen autoimmune arthritis. Annu. Rev. Immun. 2, 199–218 (1984).

    Article  CAS  Google Scholar 

  26. Trentham, D.E. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum. 25, 911–916 (1982).

    Article  CAS  Google Scholar 

  27. Flores-Romo, L. et al. Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23. Science 261, 1038–1041 (1993).

    Article  CAS  Google Scholar 

  28. Wooley, P.H. et al. Type II collagen-induced arthritis in mice. HI. Suppression of arthritis by using monoclonal and polyclonal anti-la antisera. J. Immun. 134, 2366–2374 (1985).

    CAS  PubMed  Google Scholar 

  29. Rao, M., Lee, W.T. & Conrad, D.H. Characterization of a monoclonal antibody directed against the murine B lymphocyte receptor for IgE. J. Immun. 138, 1845–1851 (1987).

    CAS  PubMed  Google Scholar 

  30. Plater-Zyberk, C., Taylor, P.C., Blaylock, M.G. & Maini, R.N. Anti-CD5 therapy decreases severity of established disease in collagen type Il-induced arthritis in DBA/1 mice. Clin. exp. Immun. 98, 442–447 (1994).

    Article  CAS  Google Scholar 

  31. Aubry, J.P., Pochon, S., Graber, P., Jansen, K.U. & Bonnefoy, J.Y. CD21 is a lig-and for CD23 and regulates IgE production. Nature 358, 505–507 (1992).

    Article  CAS  Google Scholar 

  32. Marcelletti, J.F., Ohara, J. & Katz, D.H. Collagen-induced arthritis in mice. Relationship of collagen-specific and total IgE synthesis to disease. J. Immun. 147, 4185–4191 (1991).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plater-Zyberk, C., Bonnefoy, JY. Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo. Nat Med 1, 781–785 (1995). https://doi.org/10.1038/nm0895-781

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0895-781

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing